Posts found in:
Grantees

A Pilot Study of Investigating the Effects of Glutamine and Vincristine-induced Neuropathy in Pediatric Patients with Cancer Patients with cancer are amongst the highest users of complementary/alternative therapies. Recent surveys have found 84% of pediatric oncology patients on standard anticancer protocols are taking some form of complementary/alternative medicine. However the safety of these therapies combined […]

Reproductive and sexual concerns of young women treated for lymphoma, leukemia and breast cancer Dr. Goldfarb’s team will document the impact of cancer treatment on reproductive and sexual health in young women treated for lymphoma, leukemia and breast cancer.  Premature ovarian failure and sexual dysfunction are serious problems that reduce their quality of life.  They […]

Genomics of Peripheral T-Cell Lymphoma Peripheral T-cell lymphoma (PTCL) is a group of rare diseases that collectively comprise 15 percent of lymphomas. The diseases are poorly understood and often have poor prognosis. Memorial Sloan-Kettering Cancer Center has one of the highest volumes of PTCL patients the country. This provides opportunity to study the disease by […]

The role of ATM kinase in suppression of B cell lymphomas Our lab is interested in understanding how cells sense DNA double stand breaks, integrate cell cycle progression and cellular survival to facilitate precise DNA repair and to prevent cancer-causing transformation. Defects in DNA repair machinery often lead to primary immunodeficiency and increase the risk […]

Epigenetic Programs in MLL-rearranged leukemias The Armstrong lab is using high throughput approaches that assess gene activity and chromosome structure in leukemias. Recent data suggest that certain mutations induce acute myelogenous leukemia (AML) by altering chromosome structure. The proteins that control the abnormal chromatin structure in these leukemias are enzymes (called histone methyltransferases) that present […]

Anti-CTLA Monoclonal Antibody Therapy for B Cell Lymphoma Most non-Hodgkin’s B cell lymphomas are resistant to cure with conventional chemotherapy. Paradoxically however, lymphomas are among the most susceptible of human cancers to destruction by immunologic mechanisms (T cells and antibodies). We are seeking to develop new ways to “jump start” the immune system of lymphoma […]

Targeting DNA Repair mechanisms and Tumor Protein Regulation to Treat Patients with Lymphoma Important differences exist between cancerous and normal cells in DNA repair and protein regulation.  Dr. Gerecitano is currently exploiting these differences in three clinical trials: 1) Combining ABT-888, which disables the DNA repair enzyme PARP, with bendamustine, which causes genetic damage that […]

The Role of Pro-apoptic BCL-2 Family Bid in the DNA Damage Response Programmed cell death, also called apoptosis, is a normal process that the body uses to rid itself of damaged cells. Cancer cells acquire the ability to evade this process, allowing them to live too long, as well as to resist therapeutic treatments such […]

The Role and Targets of APL-specific miRNAs in Leukemogenesis Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML), and is characterized by an excess of immature cells called promyelocytes, a form of white blood cells. Dr. Chen has recently found that a set of small RNAs, namely microRNAs, are specifically overexpressed in […]

Specific Targeting of the Leukemia-Associated Antigen FLT3 Using Chimeric Antigen Receptor (CAR)-Engineered NK Cells for Treatment of Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutations Leukemia patients with some mutations routinely relapse and have worse survival. We will engineer immune cells with the ability to specifically bind tumor cells in patients who are resistant to other […]

Therapeutic Targeting of the Oncogenic Ras Pathway in T Cell Leukemia My research group at UCSF focuses on understanding the biochemical signals inside the cell as they occur in developing cells that divide and differentiate. In parallel, we study how cancer cells have abnormal signals, what the composition is of these signals, and how these […]

In Vivo Regulation of Myeloid Cell Development and Leukemia The Rhodes laboratory is using the power of zebrafish genetics to inform on how gene mutation or abnormal activation can affect myeloid cell development and contribute to acute myelogenous leukemia (AML). They have shown that the development of zebrafish myeloid cells is surprisingly similar to humans […]